Trial Profile
Double Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly for 26 Weeks in Patients With Type 2 Diabetes Being Treated With Metformin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2019
Price :
$35
*
At a glance
- Drugs IONIS-GCGRRx (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 14 Feb 2019 Results evaluating the safety and efficacy of IONIS-GCGRRx from three phase 2 (NCT01885260, NCT02583919, NCT02824003) published in the Diabetes Care.
- 04 May 2018 Status changed from active, no longer recruiting to completed.
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.